Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Investigators Validate Role of Liquid Biopsy in Predicting Chromosomal Abnormalities in Myeloid Neoplasms

August 24th 2022

Liquid biopsy using targeted next-generation sequencing for early diagnosis and monitoring of patients with myeloid neoplasms is effective and detects chromosomal structural abnormalities.

The Future of Myeloproliferative Neoplasm Treatment

August 24th 2022

The panelists conclude their discussion by highlighting investigational agents to look forward to.

Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis

August 24th 2022

Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.

FDA Place Clinical Hold on Phase 1 Trial Examining FHD-286 in Relapsed/Refractory AML and MDS

August 23rd 2022

The FDA has placed a full clinical hold on a phase 1 dose escalation trial investigating the BRG1/BRM inhibitor FHD-286 in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.

Dr. Garcia on the Role of Ruxolitinib in Myelofibrosis

August 22nd 2022

Jacqueline S. Garcia, MD, discusses the role of ruxolitinib (Jakafi) in myelofibrosis.

Promising Data for Treatment of Myelofibrosis Emerges With Pelabresib and Ruxolitinib Combination

August 22nd 2022

John Mascarenhas, MD, discussed the effect of the data from MANIFEST on the treatment landscape and the future of adding active agents to ruxolitinib for treatment of myelofibrosis.

Myelofibrosis Treatment Approaches after Disease Progression

August 18th 2022

A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.

Clinical Scenario: A 67-Year-Old with Myelofibrosis

August 18th 2022

Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.

Dr. Ip on Next-Generation Sequencing in Myeloid Neoplasms

August 17th 2022

Andrew Ip, MD, discusses the use of targeted next-generation sequencing in detecting chromosomal structural abnormalities in patients with myeloid neoplasms.

Avapritinib Meets Primary and Secondary End Points in PIONEER Trial in Non-Advanced Systemic Mastocytosis

August 17th 2022

Treatment with avapritinib led to clinically meaningful and statistically significant improvements in patient-reported symptoms and objective measures of mast cell burden in patients with non-advanced systemic mastocytosis.

FDA Accepts NDA for Momelotinib for Treatment of Myelofibrosis

August 17th 2022

The FDA has accepted a new drug application for momelotinib for the treatment of patients with myelofibrosis.

Ruxolitinib/Pomalidomide Combo Shows Feasibility in Myelofibrosis With Anemia

August 16th 2022

A combination regimen comprised of ruxolitinib and pomalidomide was found to be safe and feasible in a cohort of intermediate-2 and high-risk patients with primary or secondary myelofibrosis and anemia, according to data from the phase 1b/2 MPNSG-0212 trial.

Management of Accelerated Phase Myeloproliferative Neoplasms

August 11th 2022

Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.

Novel Agents Under Investigation for Myelofibrosis

August 11th 2022

The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.

Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022

August 11th 2022

Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.

Efficacy and Safety of JAK Inhibitors for Myelofibrosis

August 11th 2022

Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.

Azacitidine/Quizartinib Combo Showcases Early Activity in MDS, MDS/MPN With FLT3 or CBL Mutations

August 5th 2022

The combination of azacitidine and quizartinib produced preliminary responses in patients with myelodysplastic syndrome and myelodysplastic syndrome/myeloproliferative neoplasms whose tumors harbored FLT3 or CBL mutations, according to data from a phase 1/2 trial (NCT04493138).

New JAK Inhibitors in Myelofibrosis Treatment

August 3rd 2022

Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.

Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials

August 3rd 2022

A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.

Ropeginterferon Alfa-2b Proves to be Efficacious, Safe in Japanese Patients with Polycythemia Vera

August 2nd 2022

Ropeginterferon alfa-2b produced durable complete hematologic responses without phlebotomy and showcased a consistent safety profile in Japanese patients with polycythemia vera, according to findings from a phase 2 study (NCT04182100) presented during the 2022 EHA Congress.